| Clinical and Regulatory | |
|---|---|
| Event Type: | Phase 1 Results |
| Timing: | H1 2017 |
| Designation(s): | None |
|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|
|
| Disease and Treatment | |
|---|---|
| Disease: | Respiratory |
| Indication: | Asthma and Allergic Disease |
| Lead Indication?: | No |
| Treatment Name: | XmAb7195 |
|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
|
|
| Company Information | |
|---|---|
| Co. Name: | Xencor |
| Stock Symbol: | XNCR |
| Shares Traded: | NASDAQ |
|
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
|
|
| Event Status | |
|---|---|
| Event Outcome: | Ongoing |
| Event Discussion: | Forums |
| Event Announcement(s): | http://investors.xencor.com/releasedetail.cfm?ReleaseID=977312 |
| Partnership: | No |
|
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
|
|
Detailed Event Description from Company Announcement
QuoteXmAb7195 is a first-in-class monoclonal antibody that targets IgE with its variable domain and uses Xencor's XmAb Immune Inhibitor Fc domain to target FcgRIIb, resulting in three distinct mechanisms of action for reducing IgE levels. In May 2016, Xencor presented data from a Phase 1a trial at the American Thoracic Society Annual Meeting.
Today, Xencor will discuss the recently presented data from the Phase 1a study of XmAb7195 showing that XmAb7195 was generally well tolerated and induced rapid and extensive depletion of serum IgE at all doses tested, including in high IgE subjects. A Phase 1 multiple ascending dose study with subcutaneous administration of XmAb7186 is expected to begin this year with initial data expected in the first half of 2017.